Impact of new treatment options for hepatitis C virus infection in liver transplantation

Table 6 American Association for the Study of Liver Diseases 2014 recommendations for therapy in recurrent hepatitis C virus post liver transplant

Rating	Population	CPT B and C	Regimen	Daily Dose
IB-recommended	G 1, 4 experienced and naïve	RBV 600 mg, increased as tolerated1	LDV/SOF/RBV 12 wk	90 mg/400 mg/weight-based2
IB-alternative	G 1, 4 naïve, RBV intolerant	Not recommended	LDV/SOF 24 wk	90 mg/400 mg
IB-alternative	G1	Not recommended	SOF/SMV ± RBV 12 wk	400 mg + 150 mg ± weight-based2
IB-alternative	G1	Recommended only for non-cirrhosis	Paritaprevir/r/rombitasvir/dasabuvir + RBV for 24 wk	150 mg/100 mg/25 mg/250 mg bid/weight-based2
IIB-recommended	G2 experienced and naïve	600 mg/d,	SOF/RBV 24 wk	400 mg/weight-based2
		increased as tolerated1
IB-recommended	G3 experienced and naïve	600 mg, increased as tolerated1	SOF/RBV 24 wk	400 mg/weight-based2
IIIA Not recommended: Regimens containing PEG-IFN, monotherapy with PEG-IFN, RBV, or a DAA; TVR or BOC-based regimens

¹e.g., increased monthly by 200 mg/d;

²1000 mg < 75 kg, 1200 mg > 75 kg. Recommendations are graded according the level of the evidence and strength of the recommendation. G: Genotype; RBV: Ribavirin; LDV: Ledipasvir; SOF: Sofosbuvir; RBV: Ribavirin; r: Ritonavir; DCV: Daclatasvir; DAA: Direct active antiviral; TVR: Telaprevir; BOC: Boceprevir.